Biomea Fusion (BMEA) to Post Earnings on Tuesday

Biomea Fusion (NASDAQ:BMEA) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Biomea Fusion (NASDAQ:BMEA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. On average, analysts expect Biomea Fusion to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biomea Fusion Stock Performance

Shares of Biomea Fusion stock opened at $1.26 on Tuesday. Biomea Fusion has a 1 year low of $0.87 and a 1 year high of $2.99. The firm’s 50-day simple moving average is $1.30 and its 200-day simple moving average is $1.39. The firm has a market cap of $91.10 million, a PE ratio of -1.85 and a beta of -0.31.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Biomea Fusion by 26.0% in the 4th quarter. Geode Capital Management LLC now owns 562,898 shares of the company’s stock worth $698,000 after purchasing an additional 116,024 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Biomea Fusion by 670.5% during the first quarter. AQR Capital Management LLC now owns 264,028 shares of the company’s stock valued at $562,000 after buying an additional 229,763 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Biomea Fusion by 77.1% during the third quarter. XTX Topco Ltd now owns 265,303 shares of the company’s stock worth $536,000 after buying an additional 115,524 shares during the period. Mariner LLC bought a new position in Biomea Fusion in the 3rd quarter worth approximately $483,000. Finally, State Street Corp grew its holdings in Biomea Fusion by 17.8% in the 4th quarter. State Street Corp now owns 165,115 shares of the company’s stock worth $205,000 after buying an additional 25,000 shares in the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on BMEA shares. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Biomea Fusion in a report on Tuesday, April 28th. Weiss Ratings cut Biomea Fusion from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 1st. Citizens Jmp assumed coverage on shares of Biomea Fusion in a research note on Tuesday, May 5th. They set a “market outperform” rating and a $9.00 target price for the company. Wall Street Zen cut shares of Biomea Fusion from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Citigroup started coverage on shares of Biomea Fusion in a research report on Tuesday, May 5th. They issued an “outperform” rating on the stock. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Biomea Fusion has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.